Brief: Polyphor H1 Total Loss At CHF 27.8 Mln

Spexis AG

03/09/2020 06:05

Sept 3 (Reuters) - POLYPHOR AG  POLN.S :
    * H1 LOSS -27.8 MILLION CHF
    * IN FIRST HALF OF 2020, TOTAL LOSS WAS CHF 27.8 MILLION
    * AS A RESULT OF DILIGENT FINANCIAL STEWARDSHIP WE REVISE
OUR
GUIDANCE FOR OPERATING EXPENSES TO CHF 57 MILLION TO CHF 59
MILLION FOR 2020
    * BASED ON PROJECTED CASH AND EXPECTED UPFRONT PAYMENT FROM
FOSUN
PHARMA, OUR OPERATIONS ARE FINANCED THROUGHOUT 2020 AND WELL
INTO Q3 2021
    * RESEARCH AND DEVELOPMENT COSTS IN H1 WERE PRIMARILY DRIVEN
BY
BALIXAFORTIDE PHASE III TRIAL, AND ARE EXPECTED TO DECREASE
SLIGHTLY IN Q4 2020 FOLLOWING CLOSURE OF PATIENT ENROLLMENT

Source text for Eikon:  ID:nEQ5NGG9ba 
Further company coverage:  POLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))